{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:25:51Z","timestamp":1788906351386,"version":"build-2803163510"},"publisher-location":"Cham","reference-count":119,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031920325","type":"print"},{"value":"9783031920332","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-92033-2_26","type":"book-chapter","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T17:44:09Z","timestamp":1751478249000},"page":"399-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Current Landscape of Hepcidin Therapeutics"],"prefix":"10.1007","author":[{"given":"Antonella","family":"Nai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Asperti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vinchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"3","key":"26_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ekir.2018.12.006","volume":"4","author":"O Akchurin","year":"2019","unstructured":"Akchurin O, Patino E, Dalal V, Meza K, Bhatia D, Brovender S, Zhu YS, Cunningham-Rundles S, Perelstein E, Kumar J, Rivella S, Choi ME (2019) Interleukin-6 contributes to the development of anemia in Juvenile CKD. Kidney Int Rep 4(3):470\u2013483. https:\/\/doi.org\/10.1016\/j.ekir.2018.12.006","journal-title":"Kidney Int Rep"},{"issue":"6","key":"26_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000301","volume":"3","author":"S Altamura","year":"2019","unstructured":"Altamura S, Schaeper U, Dames S, L\u00f6ffler K, Eisermann M, Frauendorf C, M\u00fcdder K, Neves J, Muckenthaler MU (2019) SLN124, a GalNAc-siRNA conjugate targeting TMPRSS6, efficiently prevents iron overload in hereditary haemochromatosis type 1. Hemasphere 3(6):e301. https:\/\/doi.org\/10.1097\/hs9.0000000000000301","journal-title":"Hemasphere"},{"issue":"12","key":"26_CR3","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1016\/j.clnu.2020.03.007","volume":"39","author":"L Alvarenga","year":"2020","unstructured":"Alvarenga L, Salarolli R, Cardozo LFMF, Santos RS, de Brito JS, Kemp JA, Reis D, de Paiva BR, Stenvinkel P, Lindholm B, Fouque D, Mafra D (2020) Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: a pilot randomized, double-blind, controlled study. Clin Nutr 39(12):3594\u20133600. https:\/\/doi.org\/10.1016\/j.clnu.2020.03.007","journal-title":"Clin Nutr"},{"key":"26_CR4","doi-asserted-by":"publisher","first-page":"40097","DOI":"10.1038\/srep40097","volume":"7","author":"S Angmo","year":"2017","unstructured":"Angmo S, Tripathi N, Abbat S, Sharma S, Singh SS, Halder A, Yadav K, Shukla G, Sandhir R, Rishi V, Bharatam PV, Yadav H, Singhal NK (2017) Identification of guanosine 5\u2032-diphosphate as potential iron mobilizer: preventing the hepcidin-ferroportin interaction and modulating the interleukin-6\/Stat-3 pathway. Sci Rep 7:40097. https:\/\/doi.org\/10.1038\/srep40097","journal-title":"Sci Rep"},{"issue":"1","key":"26_CR5","doi-asserted-by":"publisher","first-page":"17684","DOI":"10.1038\/s41598-018-35992-2","volume":"8","author":"S Angmo","year":"2018","unstructured":"Angmo S, Rana S, Yadav K, Sandhir R, Singhal NK (2018) Novel liposome eencapsulated guanosine Di phosphate based therapeutic target against anemia of inflammation. Sci Rep 8(1):17684. https:\/\/doi.org\/10.1038\/s41598-018-35992-2","journal-title":"Sci Rep"},{"issue":"2","key":"26_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1182\/blood.2024026135","volume":"145","author":"A Antypiuk","year":"2025","unstructured":"Antypiuk A, Vance S, Sharma R, Passos ST, Asperti M, Navaneethabalakrishnan S, Durrenberger F, Manolova V, Vinchi F (2025) Genetic iron overload aggravates and pharmacological iron restriction improves MDS pathophysiology in a preclinical study. Blood 145(2):155\u2013169. https:\/\/doi.org\/10.1182\/blood.2024026135","journal-title":"Blood"},{"issue":"14","key":"26_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","volume":"132","author":"J Arezes","year":"2018","unstructured":"Arezes J, Foy N, McHugh K, Sawant A, Quinkert D, Terraube V, Brinth A, Tam M, LaVallie ER, Taylor S, Armitage AE, Pasricha SR, Cunningham O, Lambert M, Draper SJ, Jasuja R, Drakesmith H (2018) Erythroferrone inhibits the induction of hepcidin by BMP6. Blood 132(14):1473\u20131477. https:\/\/doi.org\/10.1182\/blood-2018-06-857995","journal-title":"Blood"},{"issue":"8","key":"26_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1182\/blood.2019003140","volume":"135","author":"J Arezes","year":"2020","unstructured":"Arezes J, Foy N, McHugh K, Quinkert D, Benard S, Sawant A, Frost JN, Armitage AE, Pasricha SR, Lim PJ, Tam MS, Lavallie E, Pittman DD, Cunningham O, Lambert M, Murphy JE, Draper SJ, Jasuja R, Drakesmith H (2020) Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia. Blood 135(8):547\u2013557. https:\/\/doi.org\/10.1182\/blood.2019003140","journal-title":"Blood"},{"issue":"Suppl 1","key":"26_CR9","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1182\/blood-2023-178033","volume":"142","author":"S Arora","year":"2023","unstructured":"Arora S, Monroy J, Pergola P, Silva A, Buch A, Novikov N, Pelletier O, Savage W (2023) A phase 1b double-blind, placebo-controlled study of DISC-0974, an anti-hemojuvelin antibody, in patients with non-dialysis dependent chronic kidney disease and anemia. Blood 142(Suppl 1):5236\u20135236. https:\/\/doi.org\/10.1182\/blood-2023-178033","journal-title":"Blood"},{"issue":"10","key":"26_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164183","volume":"11","author":"M Asperti","year":"2016","unstructured":"Asperti M, Stuemler T, Poli M, Gryzik M, Lifshitz L, Meyron-Holtz EG, Vlodavsky I, Arosio P (2016) Heparanase overexpression reduces hepcidin expression, affects iron homeostasis and alters the response to inflammation. PLoS One 11(10):e0164183. https:\/\/doi.org\/10.1371\/journal.pone.0164183","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"26_CR12","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood-2023-181587","volume":"142","author":"M Asperti","year":"2023","unstructured":"Asperti M, Gryzik M, Cominelli M, Pagani F, Poliani PL, Girelli D, Westerberg G, \u00d6hd J, Poli M (2023) The heparinoid sevuparin improves anemia and kidney status in a mouse model of chronic kidney disease. Blood 142(Suppl 1):2463\u20132463. https:\/\/doi.org\/10.1182\/blood-2023-181587","journal-title":"Blood"},{"key":"26_CR11","doi-asserted-by":"publisher","unstructured":"Asperti M, Denardo A, Gryzik M, Persson KEM, Westerberg G, \u00d6hd J, Poli M (2024) Sevuparin strongly reduces hepcidin expression in cells, mice, and healthy human volunteers. Hemasphere 8(12):e70035. https:\/\/doi.org\/10.1002\/hem3.70035","DOI":"10.1002\/hem3.70035"},{"issue":"13","key":"26_CR13","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","volume":"129","author":"M Asshoff","year":"2017","unstructured":"Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, Seifert M, Posch W, Nairz M, Maciejewski P, Fowles P, Burns CJ, Smith G, Wagner KU, Weiss G, Whitney JA, Theurl I (2017) Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood 129(13):1823\u20131830. https:\/\/doi.org\/10.1182\/blood-2016-09-740092","journal-title":"Blood"},{"issue":"7","key":"26_CR14","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1172\/jci31342","volume":"117","author":"JL Babitt","year":"2007","unstructured":"Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY (2007) Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 117(7):1933\u20131939. https:\/\/doi.org\/10.1172\/jci31342","journal-title":"J Clin Invest"},{"issue":"13","key":"26_CR15","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood.2024023829","volume":"144","author":"S Banerjee","year":"2024","unstructured":"Banerjee S, Lu S, Jain A, Wang I, Tao H, Srinivasan S, Nemeth E, He P (2024) Targeting PKC\u03b1 alleviates iron overload in diabetes and hemochromatosis through the inhibition of ferroportin. Blood 144(13):1433\u20131444. https:\/\/doi.org\/10.1182\/blood.2024023829","journal-title":"Blood"},{"issue":"11","key":"26_CR16","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.chembiol.2019.09.004","volume":"26","author":"F B\u00e9liveau","year":"2019","unstructured":"B\u00e9liveau F, Tarkar A, Dion SP, D\u00e9silets A, Ghinet MG, Boudreault PL, St-Georges C, Marsault \u00c9, Paone D, Collins J, Macphee CH, Campobasso N, Groy A, Cottom J, Ouellette M, Pope AJ, Leduc R (2019) Discovery and development of TMPRSS6 inhibitors modulating hepcidin levels in human hepatocytes. Cell Chem Biol 26(11):1559\u20131572.e1559. https:\/\/doi.org\/10.1016\/j.chembiol.2019.09.004","journal-title":"Cell Chem Biol"},{"key":"26_CR17","doi-asserted-by":"publisher","unstructured":"Belot A, Gourbeyre O, Fay A, Palin A, Besson C, Latour C, Hopkins CR, Tidmarsh GF, Coppin H, Roth MP, Ritter MR, Hong CC, Meynard D (2019) LJ000328, a novel ALK2\/3 kinase inhibitor, represses hepcidin and significantly improves the phenotype of IRIDA. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2019.236133","DOI":"10.3324\/haematol.2019.236133"},{"issue":"10","key":"26_CR18","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/bph.13433","volume":"173","author":"M Boyce","year":"2016","unstructured":"Boyce M, Warrington S, Cortezi B, Z\u00f6llner S, Vaul\u00e9on S, Swinkels DW, Summo L, Schwoebel F, Riecke K (2016) Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects. Br J Pharmacol 173(10):1580\u20131588. https:\/\/doi.org\/10.1111\/bph.13433","journal-title":"Br J Pharmacol"},{"issue":"7","key":"26_CR19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2174\/187152008785914752","volume":"8","author":"JR Caceres-Cortes","year":"2008","unstructured":"Caceres-Cortes JR (2008) A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490. Anti Cancer Agents Med Chem 8(7):717\u2013722","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"1","key":"26_CR20","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.3324\/haematol.2015.133348","volume":"101","author":"C Casu","year":"2016","unstructured":"Casu C, Aghajan M, Oikonomidou PR, Guo S, Monia BP, Rivella S (2016a) Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia. Haematologica 101(1):e8\u2013e11. https:\/\/doi.org\/10.3324\/haematol.2015.133348","journal-title":"Haematologica"},{"issue":"2","key":"26_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","volume":"128","author":"C Casu","year":"2016","unstructured":"Casu C, Oikonomidou PR, Chen H, Nandi V, Ginzburg Y, Prasad P, Fleming RE, Shah YM, Valore EV, Nemeth E, Ganz T, MacDonald B, Rivella S (2016b) Minihepcidin peptides as disease modifiers in mice affected by \u03b2-thalassemia and polycythemia vera. Blood 128(2):265\u2013276. https:\/\/doi.org\/10.1182\/blood-2015-10-676742","journal-title":"Blood"},{"issue":"7","key":"26_CR22","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3324\/haematol.2018.212589","volume":"105","author":"C Casu","year":"2020","unstructured":"Casu C, Chessa R, Liu A, Gupta R, Drakesmith H, Fleming R, Ginzburg YZ, MacDonald B, Rivella S (2020a) Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult \u03b2-thalassemia major. Haematologica 105(7):1835\u20131844. https:\/\/doi.org\/10.3324\/haematol.2018.212589","journal-title":"Haematologica"},{"issue":"17","key":"26_CR23","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood.2019004719","volume":"136","author":"C Casu","year":"2020","unstructured":"Casu C, Pettinato M, Liu A, Aghajan M, Lo Presti V, Lidonnici MR, Munoz KA, O\u2019Hara E, Olivari V, Di Modica SM, Booten S, Guo S, Neil G, Miari R, Shapir N, Zafir-Lavie I, Domev H, Ferrari G, Sitara D, Nai A, Rivella S (2020b) Correcting \u03b2-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity. Blood 136(17):1968\u20131979. https:\/\/doi.org\/10.1182\/blood.2019004719","journal-title":"Blood"},{"issue":"12","key":"26_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251995","volume":"16","author":"C Casu","year":"2021","unstructured":"Casu C, Liu A, De Rosa G, Low A, Suzuki A, Sinha S, Ginzburg YZ, Abrams C, Aghajan M, Guo S, Rivella S (2021) Tmprss6-ASO as a tool for the treatment of Polycythemia Vera mice. PLoS One 16(12):e0251995. https:\/\/doi.org\/10.1371\/journal.pone.0251995","journal-title":"PLoS One"},{"issue":"11","key":"26_CR25","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, Tao Y, Liang X, Liu Z, Xing C, Chen J, Luo L, Zuo L, Liao Y, Liu BC, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP (2019) Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med 381(11):1001\u20131010. https:\/\/doi.org\/10.1056\/NEJMoa1813599","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"26_CR26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1182\/blood-2021-151418","volume":"138","author":"B Chen","year":"2021","unstructured":"Chen B, Wang J, Zheng B, Huang L, Mao Y, Ouyang Z, Du X (2021) Treating iron overload disorders with a novel therapeutic antibody targeting TMPRSS6. Blood 138(Suppl 1):941\u2013941. https:\/\/doi.org\/10.1182\/blood-2021-151418","journal-title":"Blood"},{"issue":"19","key":"26_CR27","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2017-04-780692","volume":"130","author":"S Colucci","year":"2017","unstructured":"Colucci S, Pagani A, Pettinato M, Artuso I, Nai A, Camaschella C, Silvestri L (2017) The immunophilin FKBP12 inhibits hepcidin expression by binding the BMP type I receptor ALK2 in hepatocytes. Blood 130(19):2111\u20132120. https:\/\/doi.org\/10.1182\/blood-2017-04-780692","journal-title":"Blood"},{"issue":"17","key":"26_CR28","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1182\/blood-2013-06-505792","volume":"122","author":"KS Cooke","year":"2013","unstructured":"Cooke KS, Hinkle B, Salimi-Moosavi H, Foltz I, King C, Rathanaswami P, Winters A, Steavenson S, Begley CG, Molineux G, Sasu BJ (2013) A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood 122(17):3054\u20133061. https:\/\/doi.org\/10.1182\/blood-2013-06-505792","journal-title":"Blood"},{"issue":"5","key":"26_CR29","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1053\/j.gastro.2010.07.044","volume":"139","author":"E Corradini","year":"2010","unstructured":"Corradini E, Schmidt PJ, Meynard D, Garuti C, Montosi G, Chen S, Vukicevic S, Pietrangelo A, Lin HY, Babitt JL (2010) BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology 139(5):1721\u20131729. https:\/\/doi.org\/10.1053\/j.gastro.2010.07.044","journal-title":"Gastroenterology"},{"key":"26_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2020.129799","volume":"2","author":"A Denardo","year":"2021","unstructured":"Denardo A, Elli S, Federici S, Asperti M, Gryzik M, Ruzzenenti P, Carmona F, Bergese P, Naggi A, Arosio P, Poli M (2021) BMP6 binding to heparin and heparan sulfate is mediated by N-terminal and C-terminal clustered basic residues. Biochim Biophys Acta Gen Subj 1865 2:129799. https:\/\/doi.org\/10.1016\/j.bbagen.2020.129799","journal-title":"Biochim Biophys Acta Gen Subj 1865"},{"issue":"15","key":"26_CR31","doi-asserted-by":"publisher","first-page":"12969","DOI":"10.1021\/acs.jmedchem.4c00922","volume":"67","author":"M Desgagn\u00e9","year":"2024","unstructured":"Desgagn\u00e9 M, D\u00e9silets A, Ferkov\u00e1 S, Lepage M, Perreault O, Joushomme A, Lemieux G, Guerrab W, Froehlich U, Comeau C, Sarret P, Leduc R, Boudreault PL (2024) Rational in silico design of selective TMPRSS6 peptidomimetic inhibitors via exploitation of the S2 subpocket. J Med Chem 67(15):12969\u201312983. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00922","journal-title":"J Med Chem"},{"issue":"5879","key":"26_CR32","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1126\/science.1157121","volume":"320","author":"X Du","year":"2008","unstructured":"Du X, She E, Gelbart T, Truksa J, Lee P, Xia Y, Khovananth K, Mudd S, Mann N, Moresco EM, Beutler E, Beutler B (2008) The serine protease TMPRSS6 is required to sense iron deficiency. Science 320(5879):1088\u20131092. https:\/\/doi.org\/10.1126\/science.1157121","journal-title":"Science"},{"issue":"5","key":"26_CR33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00109-009-0588-3","volume":"88","author":"N Fatih","year":"2010","unstructured":"Fatih N, Camberlein E, Island ML, Corlu A, Abgueguen E, D\u00e9tivaud L, Leroyer P, Brissot P, Lor\u00e9al O (2010) Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J Mol Med (Berl) 88(5):477\u2013486. https:\/\/doi.org\/10.1007\/s00109-009-0588-3","journal-title":"J Mol Med (Berl)"},{"issue":"5","key":"26_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ng.130","volume":"40","author":"KE Finberg","year":"2008","unstructured":"Finberg KE, Heeney MM, Campagna DR, Aydinok Y, Pearson HA, Hartman KR, Mayo MM, Samuel SM, Strouse JJ, Markianos K, Andrews NC, Fleming MD (2008) Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 40(5):569\u2013571. https:\/\/doi.org\/10.1038\/ng.130","journal-title":"Nat Genet"},{"issue":"6","key":"26_CR35","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2008-04-149773","volume":"112","author":"AR Folgueras","year":"2008","unstructured":"Folgueras AR, de Lara FM, Pend\u00e1s AM, Garabaya C, Rodr\u00edguez F, Astudillo A, Bernal T, Cabanillas R, L\u00f3pez-Ot\u00edn C, Velasco G (2008) Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood 112(6):2539\u20132545. https:\/\/doi.org\/10.1182\/blood-2008-04-149773","journal-title":"Blood"},{"issue":"1","key":"26_CR36","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/s41467-018-03853-1","volume":"9","author":"AR Folgueras","year":"2018","unstructured":"Folgueras AR, Freitas-Rodr\u00edguez S, Ramsay AJ, Garabaya C, Rodr\u00edguez F, Velasco G, L\u00f3pez-Ot\u00edn C (2018) Matriptase-2 deficiency protects from obesity by modulating iron homeostasis. Nat Commun 9(1):1350. https:\/\/doi.org\/10.1038\/s41467-018-03853-1","journal-title":"Nat Commun"},{"issue":"2","key":"26_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.hoc.2022.12.006","volume":"37","author":"T Ganz","year":"2023","unstructured":"Ganz T, Nemeth E (2023) Pathogenic mechanisms in thalassemia II: iron overload. Hematol Oncol Clin North Am 37(2):353\u2013363. https:\/\/doi.org\/10.1016\/j.hoc.2022.12.006","journal-title":"Hematol Oncol Clin North Am"},{"issue":"12","key":"26_CR38","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1172\/jci41717","volume":"120","author":"S Gardenghi","year":"2010","unstructured":"Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, Muirhead K, Rao N, Roy CN, Andrews NC, Nemeth E, Follenzi A, An X, Mohandas N, Ginzburg Y, Rachmilewitz EA, Giardina PJ, Grady RW, Rivella S (2010) Hepcidin as a therapeutic tool to limit iron overload and improve anemia in \u03b2-thalassemic mice. J Clin Invest 120(12):4466\u20134477. https:\/\/doi.org\/10.1172\/jci41717","journal-title":"J Clin Invest"},{"issue":"19_Suppl","key":"26_CR39","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1158\/1538-7445.am2014-3847","volume":"74","author":"P Georgiev","year":"2014","unstructured":"Georgiev P, Lazaroiu M, Ocroteala L, Grudeva-Popova J, Gheorghita E, Vasilica M, Popescu SM, Cucuianu A, Summo L, Schwoebel F, Riecke K, Ludwig H (2014) Abstract 3847: the anti-hepcidin Spiegelmer\u00ae Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: a phase II pilot study. Cancer Res 74(19_Suppl):3847\u20133847. https:\/\/doi.org\/10.1158\/1538-7445.am2014-3847","journal-title":"Cancer Res"},{"key":"26_CR40","doi-asserted-by":"publisher","unstructured":"Goncalves Monteiro D, van Dijk JWA, Aliyanto R, Fung E, Nemeth E, Ganz T, Rosengren J, Clark RJ (2021) Pursuing orally bioavailable hepcidin analogues via cyclic. Biomedicine 9(2). https:\/\/doi.org\/10.3390\/biomedicines9020164","DOI":"10.3390\/biomedicines9020164"},{"issue":"7","key":"26_CR41","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/ajh.27332","volume":"99","author":"A Guerra","year":"2024","unstructured":"Guerra A, Hamilton N, Rivera A, Demsko P, Guo S, Rivella S (2024) Combination of a TGF-\u03b2 ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting \u03b2-thalassemia. Am J Hematol 99(7):1300\u20131312. https:\/\/doi.org\/10.1002\/ajh.27332","journal-title":"Am J Hematol"},{"issue":"4","key":"26_CR42","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1172\/jci66969","volume":"123","author":"S Guo","year":"2013","unstructured":"Guo S, Casu C, Gardenghi S, Booten S, Aghajan M, Peralta R, Watt A, Freier S, Monia BP, Rivella S (2013) Reducing TMPRSS6 ameliorates hemochromatosis and \u03b2-thalassemia in mice. J Clin Invest 123(4):1531\u20131541. https:\/\/doi.org\/10.1172\/jci66969","journal-title":"J Clin Invest"},{"issue":"7","key":"26_CR43","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00296-009-1075-4","volume":"30","author":"M Hashizume","year":"2010","unstructured":"Hashizume M, Uchiyama Y, Horai N, Tomosugi N, Mihara M (2010) Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int 30(7):917\u2013923. https:\/\/doi.org\/10.1007\/s00296-009-1075-4","journal-title":"Rheumatol Int"},{"issue":"16_Suppl","key":"26_CR44","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1200\/JCO.2022.40.16_suppl.7003","volume":"40","author":"R Hoffman","year":"2022","unstructured":"Hoffman R, Ginzburg Y, Kremyanskaya M, Khanna S, Modi N, Valone FH, O\u2019Connor PG, Gupta S, Saks SR (2022) Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients. J Clin Oncol 40(16_Suppl):7003. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7003","journal-title":"J Clin Oncol"},{"issue":"7","key":"26_CR45","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/bph.14143","volume":"175","author":"AM Hohlbaum","year":"2018","unstructured":"Hohlbaum AM, Gille H, Trentmann S, Kolodziejczyk M, Rattenstetter B, Laarakkers CM, Katzmann G, Christian HJ, Andersen N, Allersdorfer A, Olwill SA, Meibohm B, Audoly LP, Swinkels DW, van Swelm RPL (2018) Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey. Br J Pharmacol 175(7):1054\u20131065. https:\/\/doi.org\/10.1111\/bph.14143","journal-title":"Br J Pharmacol"},{"key":"26_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2017.10.001","volume":"662","author":"SN Huang","year":"2018","unstructured":"Huang SN, Ruan HZ, Chen MY, Zhou G, Qian ZM (2018) Aspirin increases ferroportin 1 expression by inhibiting hepcidin via the JAK\/STAT3 pathway in interleukin 6-treated PC-12 cells. Neurosci Lett 662:1\u20135. https:\/\/doi.org\/10.1016\/j.neulet.2017.10.001","journal-title":"Neurosci Lett"},{"issue":"10","key":"26_CR47","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.3324\/haematol.2022.282328","volume":"108","author":"N Kalleda","year":"2023","unstructured":"Kalleda N, Flace A, Altermatt P, Ingoglia G, Doucerain C, Nyffenegger N, D\u00fcrrenberger F, Manolova V (2023) Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of \u03b2-thalassemia with blood transfusions. Haematologica 108(10):2703\u20132714. https:\/\/doi.org\/10.3324\/haematol.2022.282328","journal-title":"Haematologica"},{"key":"26_CR48","doi-asserted-by":"publisher","unstructured":"Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T (2014) Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. https:\/\/doi.org\/10.1038\/ng.2996","DOI":"10.1038\/ng.2996"},{"issue":"17","key":"26_CR49","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2015-07-658419","volume":"126","author":"L Kautz","year":"2015","unstructured":"Kautz L, Jung G, Du X, Gabayan V, Chapman J, Nasoff M, Nemeth E, Ganz T (2015) Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of \u03b2-thalassemia. Blood 126(17):2031\u20132037. https:\/\/doi.org\/10.1182\/blood-2015-07-658419","journal-title":"Blood"},{"key":"26_CR50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1471-2407-8-167","volume":"8","author":"H Kijima","year":"2008","unstructured":"Kijima H, Sawada T, Tomosugi N, Kubota K (2008) Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer 8:167. https:\/\/doi.org\/10.1186\/1471-2407-8-167","journal-title":"BMC Cancer"},{"issue":"5","key":"26_CR51","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.3324\/haematol.2015.140772","volume":"101","author":"S Kovac","year":"2016","unstructured":"Kovac S, B\u00f6ser P, Cui Y, Ferring-Appel D, Casarrubea D, Huang L, Fung E, Popp A, Mueller BK, Hentze MW (2016) Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels. Haematologica 101(5):e173\u2013e176. https:\/\/doi.org\/10.3324\/haematol.2015.140772","journal-title":"Haematologica"},{"issue":"12","key":"26_CR52","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S2468-1253(23)00250-9","volume":"8","author":"KV Kowdley","year":"2023","unstructured":"Kowdley KV, Modi NB, Peltekian K, Vierling JM, Ferris C, Valone FH, Gupta S (2023) Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. Lancet Gastroenterol Hepatol 8(12):1118\u20131128. https:\/\/doi.org\/10.1016\/S2468-1253(23)00250-9","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"26_CR53","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa2308809","volume":"390","author":"M Kremyanskaya","year":"2024","unstructured":"Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, Palmer J, Pettit K, Nath UK, Yacoub A, Molina A, Saks SR, Modi NB, Valone FH, Khanna S, Gupta S, Verstovsek S, Ginzburg YZ, Hoffman R, Investigators RT (2024) Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera. N Engl J Med 390(8):723\u2013735. https:\/\/doi.org\/10.1056\/NEJMoa2308809","journal-title":"N Engl J Med"},{"issue":"13","key":"26_CR54","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1158\/1078-0432.ccr-12-3349","volume":"19","author":"R Kurzrock","year":"2013","unstructured":"Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F (2013) A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 19(13):3659\u20133670. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-3349","journal-title":"Clin Cancer Res"},{"issue":"5","key":"26_CR55","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/fcp.12288","volume":"31","author":"F Lain\u00e9","year":"2017","unstructured":"Lain\u00e9 F, Laviolle B, Bardou-Jacquet E, Fatih N, Jezequel C, Collet N, Ropert M, Morcet J, Hamon C, Reymann JM, Lor\u00e9al O (2017) Curcuma decreases serum hepcidin levels in healthy volunteers: a placebo-controlled, randomized, double-blind, cross-over study. Fundam Clin Pharmacol 31(5):567\u2013573. https:\/\/doi.org\/10.1111\/fcp.12288","journal-title":"Fundam Clin Pharmacol"},{"key":"26_CR56","doi-asserted-by":"publisher","unstructured":"Lehmann EF, Liziczai M, Dro\u017cd\u017cyk K, Altermatt P, Langini C, Manolova V, Sundstrom H, D\u00fcrrenberger F, Dutzler R, Manatschal C (2023) Structures of ferroportin in complex with its specific inhibitor vamifeport. elife 12. https:\/\/doi.org\/10.7554\/eLife.83053","DOI":"10.7554\/eLife.83053"},{"issue":"2","key":"26_CR57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000504850","volume":"6","author":"ZL Li","year":"2020","unstructured":"Li ZL, Tu Y, Liu BC (2020) Treatment of renal anemia with roxadustat: advantages and achievement. Kidney Dis (Basel) 6(2):65\u201373. https:\/\/doi.org\/10.1159\/000504850","journal-title":"Kidney Dis (Basel)"},{"issue":"Suppl 1","key":"26_CR58","doi-asserted-by":"publisher","first-page":"8178","DOI":"10.1182\/blood-2022-162702","volume":"140","author":"HE Lob","year":"2022","unstructured":"Lob HE, Ivanova L, Crowell B, Kim H, Idone V, Economides AN, Hatsell SJ (2022) TMPRSS6 inhibition with a monoclonal antibody improves red blood cell health and reduces hepatic iron loading in mouse models of iron overload diseases. Blood 140(Suppl 1):8178\u20138178. https:\/\/doi.org\/10.1182\/blood-2022-162702","journal-title":"Blood"},{"issue":"Suppl_3","key":"26_CR59","doi-asserted-by":"publisher","first-page":"iii294","DOI":"10.1093\/ndt\/gfv182.08","volume":"30","author":"IC Macdougall","year":"2015","unstructured":"Macdougall IC, Rumjon A, Cinco J, Goldstein L, Summo L, Vauleon S, Riecke K (2015) FP660 pharmacokinetics and pharmacodynamics of lexaptepid, a novel anti-hepcidin molecule, in ESA-resistant haemodialysis patients. Nephrol Dial Transplant 30(Suppl_3):iii294\u2013iii295. https:\/\/doi.org\/10.1093\/ndt\/gfv182.08","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"26_CR60","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI129382","volume":"130","author":"V Manolova","year":"2019","unstructured":"Manolova V, Nyffenegger N, Flace A, Altermatt P, Varol A, Doucerain C, Sundstrom H, D\u00fcrrenberger F (2019) Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of \u03b2-thalassemia. J Clin Invest 130(1):491\u2013506. https:\/\/doi.org\/10.1172\/JCI129382","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"26_CR61","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1182\/blood-2018-99-115339","volume":"132","author":"M McCaleb","year":"2018","unstructured":"McCaleb M, Lickliter J, Dibble A, Schneider E, Aghajan M, Guo S, Hughes S, Geary RS, Monia BP (2018) Transmembrane protease, serine 6 (TMPRSS6) antisense oligonucleotide (IONIS-TMPRSS6-LRX) reduces plasma iron levels of healthy volunteers in a phase 1 clinical study. Blood 132(Suppl 1):3634\u20133634. https:\/\/doi.org\/10.1182\/blood-2018-99-115339","journal-title":"Blood"},{"issue":"21","key":"26_CR62","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1182\/blood-2012-01-401885","volume":"119","author":"A Nai","year":"2012","unstructured":"Nai A, Pagani A, Mandelli G, Lidonnici MR, Silvestri L, Ferrari G, Camaschella C (2012) Deletion of TMPRSS6 attenuates the phenotype in a mouse model of \u03b2-thalassemia. Blood 119(21):5021\u20135029. https:\/\/doi.org\/10.1182\/blood-2012-01-401885","journal-title":"Blood"},{"issue":"8","key":"26_CR63","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.leukres.2012.04.006","volume":"36","author":"J Neukirchen","year":"2012","unstructured":"Neukirchen J, Fox F, K\u00fcndgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N (2012) Improved survival in MDS patients receiving iron chelation therapy\u2014a matched pair analysis of 188 patients from the D\u00fcsseldorf MDS registry. Leuk Res 36(8):1067\u20131070. https:\/\/doi.org\/10.1016\/j.leukres.2012.04.006","journal-title":"Leuk Res"},{"key":"26_CR64","unstructured":"Nicholls A, Lickliter J, Tozzi L, Liu D, Shames R (2018) Hepcidin mimetic ptg-300 induces dose-related and sustained reductions in serum iron and transferrin saturation in healthy subjects. In: EHA Library (https:\/\/library.ehaweb.org\/) of the 23rd EHA Congress"},{"issue":"8","key":"26_CR65","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/jcph.2432","volume":"64","author":"N Novikov","year":"2024","unstructured":"Novikov N, Buch A, Yang H, Andruk M, Liu G, Wu M, Howell H, MacDonald B, Savage W (2024) First-in-human phase 1 study evaluating the safety, pharmacokinetics, and pharmacodynamics of DISC-0974, an anti-hemojuvelin antibody, in healthy participants. J Clin Pharmacol 64(8):953\u2013962. https:\/\/doi.org\/10.1002\/jcph.2432","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"26_CR66","doi-asserted-by":"publisher","first-page":"224","DOI":"10.34067\/KID.0005862020","volume":"2","author":"KL Nowak","year":"2021","unstructured":"Nowak KL, Kakkar R, Devalaraja M, Lo L, Park W, Gobburu J, Kling D, Davidson M, Chonchol M (2021) A phase 1 randomized dose-escalation study of a human monoclonal antibody to IL-6 in CKD. Kidney 360 2(2):224\u2013235. https:\/\/doi.org\/10.34067\/KID.0005862020","journal-title":"Kidney 360"},{"key":"26_CR67","doi-asserted-by":"publisher","unstructured":"Nyffenegger N, Flace A, Doucerain C, D\u00fcrrenberger F, Manolova V (2021) The oral ferroportin inhibitor VIT-2763 improves erythropoiesis without interfering with iron chelation therapy in a mouse model of \u03b2-thalassemia. Int J Mol Sci 22(2). https:\/\/doi.org\/10.3390\/ijms22020873","DOI":"10.3390\/ijms22020873"},{"issue":"7","key":"26_CR68","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1182\/blood.2021014716","volume":"140","author":"N Nyffenegger","year":"2022","unstructured":"Nyffenegger N, Zennadi R, Kalleda N, Flace A, Ingoglia G, Buzzi RM, Doucerain C, Buehler PW, Schaer DJ, D\u00fcrrenberger F, Manolova V (2022) The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease. Blood 140(7):769\u2013781. https:\/\/doi.org\/10.1182\/blood.2021014716","journal-title":"Blood"},{"issue":"9","key":"26_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.147","volume":"8","author":"N Nyffenegger","year":"2024","unstructured":"Nyffenegger N, Flace A, Varol A, Altermatt P, Doucerain C, Sundstrom H, D\u00fcrrenberger F, Manolova V (2024) The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis. Hemasphere 8(9):e147. https:\/\/doi.org\/10.1002\/hem3.147","journal-title":"Hemasphere"},{"key":"26_CR70","doi-asserted-by":"publisher","unstructured":"Patel AB, Masarova L, Mesa RA, Hobbs G, Pemmaraju N (2024) Polycythemia vera: past, present and future. Leuk Lymphoma:1\u201313. https:\/\/doi.org\/10.1080\/10428194.2024.2361836","DOI":"10.1080\/10428194.2024.2361836"},{"issue":"1","key":"26_CR71","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1681\/ASN.2020050595","volume":"32","author":"PE Pergola","year":"2021","unstructured":"Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS, Smith MT, Lo L, Herzog K, Kakkar R, Davidson MH (2021) Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1\/2 multicenter, randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol 32(1):211\u2013222. https:\/\/doi.org\/10.1681\/ASN.2020050595","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"26_CR72","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/ajh.26961","volume":"98","author":"M Pettinato","year":"2023","unstructured":"Pettinato M, Dulja A, Colucci S, Furiosi V, Fette F, Steinbicker AU, Muckenthaler MU, Nai A, Pagani A, Silvestri L (2023) FKBP12 inhibits hepcidin expression by modulating BMP receptors interaction and ligand responsiveness in hepatocytes. Am J Hematol 98(8):1223\u20131235. https:\/\/doi.org\/10.1002\/ajh.26961","journal-title":"Am J Hematol"},{"issue":"3","key":"26_CR73","doi-asserted-by":"publisher","first-page":"G310","DOI":"10.1152\/ajpgi.00305.2023","volume":"326","author":"M Pettinato","year":"2024","unstructured":"Pettinato M, Aghajan M, Guo S, Bavuso Volpe L, Carleo R, Nai A, Pagani A, Altamura S, Silvestri L (2024) A functional interplay between the two BMP-SMAD pathway inhibitors TMPRSS6 and FKBP12 regulates. Am J Physiol Gastrointest Liver Physiol 326(3):G310\u2013G317. https:\/\/doi.org\/10.1152\/ajpgi.00305.2023","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"9","key":"26_CR74","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1182\/blood.2019004653","volume":"136","author":"V Petzer","year":"2020","unstructured":"Petzer V, Tymoszuk P, Asshoff M, Carvalho J, Papworth J, Deantonio C, Bayliss L, Wake MS, Seifert M, Brigo N, Valente de Souza L, Hilbe R, Grubwieser P, Demetz E, Dichtl S, Volani C, Berger S, B\u00f6hm F, Hoffmann A, Pfeifhofer-Obermair C, von Raffay L, Sopper S, Arndt S, Bosserhoff A, Kautz L, Perrier P, Nairz M, Wolf D, Weiss G, Germaschewski V, Theurl I (2020) A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease. Blood 136(9):1080\u20131090. https:\/\/doi.org\/10.1182\/blood.2019004653","journal-title":"Blood"},{"key":"26_CR75","doi-asserted-by":"publisher","unstructured":"Pilo F, Angelucci E (2024) Vamifeport: monography of the first oral ferroportin inhibitor. J Clin Med 13(18). https:\/\/doi.org\/10.3390\/jcm13185524","DOI":"10.3390\/jcm13185524"},{"issue":"3","key":"26_CR76","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1182\/blood-2010-06-289082","volume":"117","author":"M Poli","year":"2011","unstructured":"Poli M, Girelli D, Campostrini N, Maccarinelli F, Finazzi D, Luscieti S, Nai A, Arosio P (2011) Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood 117(3):997\u20131004. https:\/\/doi.org\/10.1182\/blood-2010-06-289082","journal-title":"Blood"},{"issue":"10","key":"26_CR77","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1182\/blood-2013-07-515221","volume":"123","author":"M Poli","year":"2014","unstructured":"Poli M, Asperti M, Naggi A, Campostrini N, Girelli D, Corbella M, Benzi M, Besson-Fournier C, Coppin H, Maccarinelli F, Finazzi D, Arosio P (2014a) Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood 123(10):1564\u20131573. https:\/\/doi.org\/10.1182\/blood-2013-07-515221","journal-title":"Blood"},{"issue":"3","key":"26_CR78","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bcp.2014.09.007","volume":"92","author":"M Poli","year":"2014","unstructured":"Poli M, Asperti M, Ruzzenenti P, Mandelli L, Campostrini N, Martini G, Di Somma M, Maccarinelli F, Girelli D, Naggi A, Arosio P (2014b) Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo. Biochem Pharmacol 92(3):467\u2013475. https:\/\/doi.org\/10.1016\/j.bcp.2014.09.007","journal-title":"Biochem Pharmacol"},{"issue":"36","key":"26_CR79","doi-asserted-by":"publisher","first-page":"13292","DOI":"10.1074\/jbc.RA118.007213","volume":"294","author":"M Poli","year":"2019","unstructured":"Poli M, Anower-E-Khuda F, Asperti M, Ruzzenenti P, Gryzik M, Denardo A, Gordts PLSM, Arosio P, Esko JD (2019) Hepatic heparan sulfate is a master regulator of hepcidin expression and iron homeostasis in human hepatocytes and mice. J Biol Chem 294(36):13292\u201313303. https:\/\/doi.org\/10.1074\/jbc.RA118.007213","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"26_CR80","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood-2018-99-110885","volume":"132","author":"J Porter","year":"2018","unstructured":"Porter J, Kowdley K, Taher A, Vacirca J, Shen Z, Chen S, Chawla L, Tidmarsh G (2018) Effect of Ljpc-401 (synthetic human hepcidin) on iron parameters in healthy adults. Blood 132(Suppl 1):2336\u20132336. https:\/\/doi.org\/10.1182\/blood-2018-99-110885","journal-title":"Blood"},{"issue":"9","key":"26_CR81","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/ajh.27015","volume":"98","author":"JB Porter","year":"2023","unstructured":"Porter JB, Scrimgeour A, Martinez A, James L, Aleku M, Wilson R, Muckenthaler M, Boyce M, Wilkes D, Schaeper U, Campion GV (2023) SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers. Am J Hematol 98(9):1425\u20131435. https:\/\/doi.org\/10.1002\/ajh.27015","journal-title":"Am J Hematol"},{"issue":"12","key":"26_CR82","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1172\/JCI57693","volume":"121","author":"GC Preza","year":"2011","unstructured":"Preza GC, Ruchala P, Pinon R, Ramos E, Qiao B, Peralta MA, Sharma S, Waring A, Ganz T, Nemeth E (2011) Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest 121(12):4880\u20134888. https:\/\/doi.org\/10.1172\/JCI57693","journal-title":"J Clin Invest"},{"issue":"18","key":"26_CR83","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2012-07-440743","volume":"120","author":"E Ramos","year":"2012","unstructured":"Ramos E, Ruchala P, Goodnough JB, Kautz L, Preza GC, Nemeth E, Ganz T (2012) Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 120(18):3829\u20133836. https:\/\/doi.org\/10.1182\/blood-2012-07-440743","journal-title":"Blood"},{"issue":"3","key":"26_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212023","volume":"14","author":"L Renders","year":"2019","unstructured":"Renders L, Budde K, Rosenberger C, van Swelm R, Swinkels D, Dellanna F, Feuerer W, Wen M, Erley C, Bader B, Sommerer C, Schaier M, Meurer K, Matis L (2019) First-in-human phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. PLoS One 14(3):e0212023. https:\/\/doi.org\/10.1371\/journal.pone.0212023","journal-title":"PLoS One"},{"issue":"1","key":"26_CR85","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajh.25670","volume":"95","author":"F Richard","year":"2020","unstructured":"Richard F, van Lier JJ, Roubert B, Haboubi T, G\u00f6hring UM, D\u00fcrrenberger F (2020) Oral ferroportin inhibitor VIT-2763: first-in-human, phase 1 study in healthy volunteers. Am J Hematol 95(1):68\u201377. https:\/\/doi.org\/10.1002\/ajh.25670","journal-title":"Am J Hematol"},{"issue":"7","key":"26_CR86","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.leukres.2009.12.004","volume":"34","author":"C Rose","year":"2010","unstructured":"Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P, My\u00e9lodysplasies GGFd (2010) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des My\u00e9lodysplasies). Leuk Res 34(7):864\u2013870. https:\/\/doi.org\/10.1016\/j.leukres.2009.12.004","journal-title":"Leuk Res"},{"issue":"Suppl 1","key":"26_CR87","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1182\/blood-2023-187643","volume":"142","author":"S Rottey","year":"2023","unstructured":"Rottey S, Singh N, Labriola-Tompkins E, Lob HE, Mohammadi K, Hassan H, Farrelly L, Duggal S, Chin H, Hatsell S, Burczynski ME, Harari O, Perlee L, Van Lancker G (2023) Single ascending doses of REGN7999, a monoclonal antibody inhibitor of TMPRSS6, increase serum hepcidin and cause deep, sustained reductions in serum iron in healthy human volunteers. Blood 142(Suppl 1):3841\u20133841. https:\/\/doi.org\/10.1182\/blood-2023-187643","journal-title":"Blood"},{"issue":"13","key":"26_CR88","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1182\/blood.2023022724","volume":"143","author":"U Sardo","year":"2024","unstructured":"Sardo U, Perrier P, Cormier K, Sotin M, Personnaz J, Medjbeur T, Desquesnes A, Cannizzo L, Ruiz-Martinez M, Thevenin J, Billor\u00e9 B, Jung G, Abboud E, Peyssonnaux C, Nemeth E, Ginzburg YZ, Ganz T, Kautz L (2024) The hepatokine FGL1 regulates hepcidin and iron metabolism during anemia in mice by antagonizing BMP signaling. Blood 143(13):1282\u20131292. https:\/\/doi.org\/10.1182\/blood.2023022724","journal-title":"Blood"},{"issue":"Suppl_2","key":"26_CR89","doi-asserted-by":"publisher","first-page":"ii43","DOI":"10.1093\/rheumatology\/kex513","volume":"57","author":"G Schett","year":"2018","unstructured":"Schett G (2018) Physiological effects of modulating the interleukin-6 axis. Rheumatology (Oxford) 57(Suppl_2):ii43\u2013ii50. https:\/\/doi.org\/10.1093\/rheumatology\/kex513","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"26_CR90","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/ajh.23934","volume":"90","author":"PJ Schmidt","year":"2015","unstructured":"Schmidt PJ, Racie T, Westerman M, Fitzgerald K, Butler JS, Fleming MD (2015) Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of \u03b2-thalassemia intermedia. Am J Hematol 90(4):310\u2013313. https:\/\/doi.org\/10.1002\/ajh.23934","journal-title":"Am J Hematol"},{"issue":"6","key":"26_CR91","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ajh.25079","volume":"93","author":"PJ Schmidt","year":"2018","unstructured":"Schmidt PJ, Liu K, Visner G, Fitzgerald K, Fishman S, Racie T, Hettinger JL, Butler JS, Fleming MD (2018) RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of \u03b2-thalassemia intermedia. Am J Hematol 93(6):745\u2013750. https:\/\/doi.org\/10.1002\/ajh.25079","journal-title":"Am J Hematol"},{"issue":"12","key":"26_CR92","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1182\/blood-2012-09-456756","volume":"121","author":"F Schwoebel","year":"2013","unstructured":"Schwoebel F, van Eijk LT, Zboralski D, Sell S, Buchner K, Maasch C, Purschke WG, Humphrey M, Z\u00f6llner S, Eulberg D, Morich F, Pickkers P, Klussmann S (2013) The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood 121(12):2311\u20132315. https:\/\/doi.org\/10.1182\/blood-2012-09-456756","journal-title":"Blood"},{"issue":"1","key":"26_CR93","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.kint.2020.01.025","volume":"98","author":"Y Scindia","year":"2020","unstructured":"Scindia Y, Wlazlo E, Ghias E, Cechova S, Loi V, Leeds J, Ledesma J, Helen C, Swaminathan S (2020) Modulation of iron homeostasis with hepcidin ameliorates spontaneous murine lupus nephritis. Kidney Int 98(1):100\u2013115. https:\/\/doi.org\/10.1016\/j.kint.2020.01.025","journal-title":"Kidney Int"},{"issue":"6","key":"26_CR94","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.jhep.2013.05.045","volume":"59","author":"A Sehgal","year":"2013","unstructured":"Sehgal A, Vaishnaw A, Fitzgerald K (2013) Liver as a target for oligonucleotide therapeutics. J Hepatol 59(6):1354\u20131359. https:\/\/doi.org\/10.1016\/j.jhep.2013.05.045","journal-title":"J Hepatol"},{"issue":"5","key":"26_CR95","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/bcp.13877","volume":"85","author":"M Sheetz","year":"2019","unstructured":"Sheetz M, Barrington P, Callies S, Berg PH, McColm J, Marbury T, Decker B, Dyas GL, Truhlar SME, Benschop R, Leung D, Berg J, Witcher DR (2019) Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol 85(5):935\u2013948. https:\/\/doi.org\/10.1111\/bcp.13877","journal-title":"Br J Clin Pharmacol"},{"key":"26_CR96","doi-asserted-by":"publisher","unstructured":"Shen Y, Li X, Su Y, Badshah SA, Zhang B, Xue Y, Shang P (2019) Downregulation contributes to aggressive hepatocellular carcinoma via mechanism mediated by cyclin4-dependent kinase-1\/STAT3 pathway. Diagnostics (Basel) 9(2). https:\/\/doi.org\/10.3390\/diagnostics9020048","DOI":"10.3390\/diagnostics9020048"},{"issue":"6","key":"26_CR97","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.cmet.2008.09.012","volume":"8","author":"L Silvestri","year":"2008","unstructured":"Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C (2008) The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 8(6):502\u2013511. https:\/\/doi.org\/10.1016\/j.cmet.2008.09.012","journal-title":"Cell Metab"},{"issue":"18","key":"26_CR98","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1182\/blood-2010-03-271791","volume":"116","author":"SN Song","year":"2010","unstructured":"Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K (2010) Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 116(18):3627\u20133634. https:\/\/doi.org\/10.1182\/blood-2010-03-271791","journal-title":"Blood"},{"issue":"17","key":"26_CR99","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2022017976","volume":"141","author":"J Stetka","year":"2023","unstructured":"Stetka J, Usart M, Kubovcakova L, Rai S, Rao TN, Sutter J, Hao-Shen H, Dirnhofer S, Geier F, Bader MS, Passweg JR, Manolova V, D\u00fcrrenberger F, Ahmed N, Schroeder T, Ganz T, Nemeth E, Silvestri L, Nai A, Camaschella C, Skoda RC (2023) Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood 141(17):2127\u20132140. https:\/\/doi.org\/10.1182\/blood.2022017976","journal-title":"Blood"},{"issue":"7","key":"26_CR100","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nbt.1644","volume":"28","author":"T Tang","year":"2010","unstructured":"Tang T, Li L, Tang J, Li Y, Lin WY, Martin F, Grant D, Solloway M, Parker L, Ye W, Forrest W, Ghilardi N, Oravecz T, Platt KA, Rice DS, Hansen GM, Abuin A, Eberhart DE, Godowski P, Holt KH, Peterson A, Zambrowicz BP, de Sauvage FJ (2010) A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol 28(7):749\u2013755. https:\/\/doi.org\/10.1038\/nbt.1644","journal-title":"Nat Biotechnol"},{"issue":"7","key":"26_CR101","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/ajh.27336","volume":"99","author":"E Tanzi","year":"2024","unstructured":"Tanzi E, Di Modica SM, Bordini J, Olivari V, Pagani A, Furiosi V, Silvestri L, Campanella A, Nai A (2024) Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in \u03b2-thalassemic mice. Am J Hematol 99(7):1313\u20131325. https:\/\/doi.org\/10.1002\/ajh.27336","journal-title":"Am J Hematol"},{"key":"26_CR102","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2019-129309","volume":"134","author":"R Taranath","year":"2019","unstructured":"Taranath R, Bourne G, Zhao L, Frederick B, King C, Liu D (2019) Regulation of iron homeostasis by PTG-300 improves disease parameters in mouse models for beta-thalassemia and hereditary hemochromatosis. Blood 134:3540. https:\/\/doi.org\/10.1182\/blood-2019-129309","journal-title":"Blood"},{"issue":"Suppl 1","key":"26_CR103","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1182\/blood-2022-171139","volume":"140","author":"R Taranath","year":"2022","unstructured":"Taranath R, Dion C, Bhandari A, Liu DY (2022) Rusfertide Analog-PN23114 as a hepcidin mimetic provides efficacy benefits in conjunction with phlebotomy in mouse model for hereditary hemochromatosis. Blood 140(Suppl 1):5345\u20135345. https:\/\/doi.org\/10.1182\/blood-2022-171139","journal-title":"Blood"},{"issue":"1","key":"26_CR104","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-024-01029-3","volume":"14","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Pardanani A (2024) Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval. Blood Cancer J 14(1):47. https:\/\/doi.org\/10.1038\/s41408-024-01029-3","journal-title":"Blood Cancer J"},{"issue":"18","key":"26_CR105","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1182\/blood-2011-03-345066","volume":"118","author":"I Theurl","year":"2011","unstructured":"Theurl I, Schroll A, Sonnweber T, Nairz M, Theurl M, Willenbacher W, Eller K, Wolf D, Seifert M, Sun CC, Babitt JL, Hong CC, Menhall T, Gearing P, Lin HY, Weiss G (2011) Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 118(18):4977\u20134984. https:\/\/doi.org\/10.1182\/blood-2011-03-345066","journal-title":"Blood"},{"issue":"2","key":"26_CR106","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12870","volume":"48","author":"S Udali","year":"2018","unstructured":"Udali S, Castagna A, Corbella M, Ruzzenente A, Moruzzi S, Mazzi F, Campagnaro T, De Santis D, Franceschi A, Pattini P, Gottardo R, Olivieri O, Perbellini L, Guglielmi A, Choi SW, Girelli D, Friso S (2018) Hepcidin and DNA promoter methylation in hepatocellular carcinoma. Eur J Clin Investig 48(2):e12870. https:\/\/doi.org\/10.1111\/eci.12870","journal-title":"Eur J Clin Investig"},{"issue":"1","key":"26_CR107","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","volume":"10","author":"S Vadhan-Raj","year":"2017","unstructured":"Vadhan-Raj S, Abonour R, Goldman JW, Smith DA, Slapak CA, Ilaria RL, Tiu RV, Wang X, Callies S, Cox J, Tuttle JL, Lau YK, Roeland EJ (2017) A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol 10(1):73. https:\/\/doi.org\/10.1186\/s13045-017-0427-x","journal-title":"J Hematol Oncol"},{"issue":"1","key":"26_CR108","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/bjh.17428","volume":"194","author":"J Vadolas","year":"2021","unstructured":"Vadolas J, Ng GZ, Kysenius K, Crouch PJ, Dames S, Eisermann M, Nualkaew T, Vilcassim S, Schaeper U, Grigoriadis G (2021) SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of \u03b2-thalassaemia. Br J Haematol 194(1):200\u2013210. https:\/\/doi.org\/10.1111\/bjh.17428","journal-title":"Br J Haematol"},{"issue":"17","key":"26_CR109","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/blood-2014-03-559484","volume":"124","author":"LT van Eijk","year":"2014","unstructured":"van Eijk LT, John AS, Schwoebel F, Summo L, Vaul\u00e9on S, Z\u00f6llner S, Laarakkers CM, Kox M, van der Hoeven JG, Swinkels DW, Riecke K, Pickkers P (2014) Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood 124(17):2643\u20132646. https:\/\/doi.org\/10.1182\/blood-2014-03-559484","journal-title":"Blood"},{"issue":"23","key":"26_CR110","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1200\/jco.2009.27.2377","volume":"28","author":"F van Rhee","year":"2010","unstructured":"van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman\u2019s disease. J Clin Oncol 28(23):3701\u20133708. https:\/\/doi.org\/10.1200\/jco.2009.27.2377","journal-title":"J Clin Oncol"},{"issue":"1","key":"26_CR111","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1182\/blood-2006-07-033969","volume":"109","author":"MV Verga Falzacappa","year":"2007","unstructured":"Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU (2007) STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109(1):353\u2013358. https:\/\/doi.org\/10.1182\/blood-2006-07-033969","journal-title":"Blood"},{"issue":"3","key":"26_CR112","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000357","volume":"4","author":"F Vinchi","year":"2020","unstructured":"Vinchi F, Hell S, Platzbecker U (2020) Controversies on the consequences of iron overload and chelation in MDS. Hemasphere 4(3):e357. https:\/\/doi.org\/10.1097\/HS9.0000000000000357","journal-title":"Hemasphere"},{"issue":"8","key":"26_CR113","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1182\/bloodadvances.2023012010","volume":"8","author":"M Wake","year":"2024","unstructured":"Wake M, Palin A, Belot A, Berger M, Lorgouilloux M, Bichon M, Papworth J, Bayliss L, Grimshaw B, Rynkiewicz N, Paterson J, Poindron A, Spearing E, Carter E, Hudson R, Campbell M, Petzer V, Besson-Fournier C, Latour C, Largounez A, Gourbeyre O, Fay A, Coppin H, Roth MP, Theurl I, Germaschewski V, Meynard D (2024) A human anti-matriptase-2 antibody limits iron overload, \u03b1-globin aggregates, and splenomegaly in \u03b2-thalassemic mice. Blood Adv 8(8):1898\u20131907. https:\/\/doi.org\/10.1182\/bloodadvances.2023012010","journal-title":"Blood Adv"},{"issue":"6","key":"26_CR114","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood.2019002620","volume":"135","author":"CY Wang","year":"2020","unstructured":"Wang CY, Xu Y, Traeger L, Dogan DY, Xiao X, Steinbicker AU, Babitt JL (2020) Erythroferrone lowers hepcidin by sequestering BMP2\/6 heterodimer from binding to the BMP type I receptor ALK3. Blood 135(6):453\u2013456. https:\/\/doi.org\/10.1182\/blood.2019002620","journal-title":"Blood"},{"issue":"1","key":"26_CR115","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","volume":"133","author":"G Weiss","year":"2019","unstructured":"Weiss G, Ganz T, Goodnough LT (2019) Anemia of inflammation. Blood 133(1):40\u201350. https:\/\/doi.org\/10.1182\/blood-2018-06-856500","journal-title":"Blood"},{"issue":"21","key":"26_CR116","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1182\/blood.V122.21.3433.3433","volume":"122","author":"DR Witcher","year":"2013","unstructured":"Witcher DR, Leung D, Hill KA, De Rosa DC, Xu J, Manetta J, Wroblewski VJ, Benschop RJ (2013) LY2928057, an antibody targeting ferroportin, is a potent inhibitor of hepcidin activity and increases iron mobilization in normal cynomolgus monkeys. Blood 122(21):3433\u20133433. https:\/\/doi.org\/10.1182\/blood.V122.21.3433.3433","journal-title":"Blood"},{"issue":"Suppl 1","key":"26_CR117","doi-asserted-by":"publisher","first-page":"8153","DOI":"10.1182\/blood-2022-169552","volume":"140","author":"M Wu","year":"2022","unstructured":"Wu M, Wang K, MacDonald B (2022) DISC-0974, an anti-hemojuvelin (HJV) monoclonal antibody, reduced hepcidin and improved anemia in a rat model of chronic kidney disease. Blood 140(Suppl 1):8153\u20138154. https:\/\/doi.org\/10.1182\/blood-2022-169552","journal-title":"Blood"},{"issue":"12","key":"26_CR118","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1182\/blood.2024024293","volume":"144","author":"T Xu","year":"2024","unstructured":"Xu T, Zhang X, Zhao W, Shi J, Wan S, Zhang Y, Hao Y, Sun M, He J, Jiang L, Wang H, Gao H, Luo J, Luo Y, An P (2024) Foxo1 is an iron-responsive transcriptional factor regulating systemic iron homeostasis. Blood 144(12):1314\u20131328. https:\/\/doi.org\/10.1182\/blood.2024024293","journal-title":"Blood"},{"issue":"45","key":"26_CR119","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.3748\/wjg.v17.i45.5032","volume":"17","author":"SP Zhang","year":"2011","unstructured":"Zhang SP, Wang Z, Wang LX, Liu SJ (2011) AG490: an inhibitor of hepcidin expression in vivo. World J Gastroenterol 17(45):5032\u20135034. https:\/\/doi.org\/10.3748\/wjg.v17.i45.5032","journal-title":"World J Gastroenterol"}],"container-title":["Advances in Experimental Medicine and Biology","Iron Metabolism in Human Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-92033-2_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:56:06Z","timestamp":1776797766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-92033-2_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031920325","9783031920332"],"references-count":119,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-92033-2_26","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"3 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}